After the approval of the AI RSV vaccine clinical trial, what challenges does Wantai Biological face?

On March 16, 2026, Wantai Biological announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. The recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) developed in collaboration with Xiamen University has officially been approved to conduct clinical trials.

Image source: Company announcement

Longer Approval Cycles Generally

This vaccine uses CHOZN® cells as the vector, with the core active component being the self-developed RSV fusion pre-fusion membrane fusion protein F. Preclinical data show good safety, and it can induce specific protective immune responses in mice, rats, crab-eating macaques, and other animals. The indication is for preventing lower respiratory tract diseases caused by RSV infection.

From acceptance on December 17, 2025, to approval for clinical trials, it took only about three months, demonstrating regulatory recognition of the R&D quality. The company also notes that the vaccine must complete Phase I/II/III clinical trials, marketing review, GMP inspection, and other procedures, which generally result in long approval cycles.

The clinical approval of this RSV vaccine comes at a critical point when Wantai Biological’s performance is under deep pressure and its business structure is undergoing transformation.

From the perspective of product value and industry trends, the RSV vaccine is not only a billion-yuan blue ocean in the domestic vaccine market but also a key move in Wantai’s restructuring of growth logic.

Respiratory syncytial virus is a major pathogen causing severe respiratory infections in infants, the elderly, and immunocompromised populations. The number of infections domestically is large each year. Globally, only GSK, Pfizer, and Moderna have marketed RSV vaccines, leaving a gap in the domestic market with huge unmet demand.

Imminent Competition

Industry estimates suggest that China’s RSV vaccine market could surpass 15 billion yuan by 2030, with a compound annual growth rate exceeding 50%. It is expected to become a major blue ocean in vaccines after HPV and shingles.

Wantai’s RSV vaccine adopts a mature recombinant protein route based on CHO cells, leveraging the company’s and Xiamen University’s vaccine platform technology. The process is stable, safety is controllable, and the fusion pre-F protein target aligns with global mainstream approaches, providing a solid foundation for industrialization.

However, companies like Mikrogen have already entered Phase III clinical trials, and dozens of players including Sinovac, Zhifei, and Watson are deploying various technological routes such as recombinant protein, mRNA, and viral vectors. International giants like GSK have also submitted marketing applications domestically. The competition between domestic and international companies is imminent.

Wantai Biological is still in the early clinical stage, with progress relatively behind. Even if development proceeds smoothly, market approval may take 3–5 years, by which time the market landscape could be already shaped, and first-mover advantages and pricing power may be limited.

Time as a Strategic Buffer

For Wantai Biological, the RSV vaccine is a key part of its strategic shift away from HPV dependence and toward a more complete vaccine portfolio. It is expected to synergize with existing products like hepatitis E, HPV, and rotavirus, leveraging the company’s mature channels and academic promotion capabilities to achieve commercial volume and support long-term valuation restructuring.

However, several risks should be noted: First, clinical failure risk—RSV vaccines have strict requirements for immunogenicity, efficacy, and safety, and many global projects have failed in clinical phases. The data from Phase III trials are highly uncertain.

Second, competitive intensification risk—an increasingly crowded field with international giants entering, likely leading to price wars and squeezed profit margins.

Third, cycle mismatch risk—the long R&D and commercialization cycle of 5–8 years, combined with the company’s current losses and cash flow pressures, means large long-term investments could continue to weigh on short-term profitability.

Fourth, policy risks—future medical insurance inclusion, centralized procurement expansion, and vaccination policy adjustments could alter market size and pricing logic.

In summary, the RSV vaccine is a major product in Wantai’s transformation, essentially a strategic move to buy time and space. Whether it can realize its value remains to be seen over time.

Readers are reminded: This article is based on publicly available information or responses from interviewees. The author does not guarantee the completeness or accuracy of the information. Under no circumstances does this content constitute investment advice. Market risks exist; invest cautiously! Reproduction or plagiarism without permission is prohibited!